Search
T-5224
go.drugbank.com/drugs/DB05998ExperimentalT-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.
XP21279
go.drugbank.com/drugs/DB06319InvestigationalXP21279 is a prodrug of [Levodopa], a dopamine precursor used in the management of Parkinson's disease.
Octyl triazone
go.drugbank.com/drugs/DB15469InvestigationalMixtures: Kiehls Ultra Light Daily UV Defense Aqua Gel SPF 50 Anti-PollutionMBO7133
go.drugbank.com/drugs/DB04999ExperimentalMB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. … However, araC is only slowly converted to araCTP in the liver or in primary liver tumors due to low levels of an enzyme in the liver that is required for the conversion of araC to araCMP, the first step
REN-850
go.drugbank.com/drugs/DB05912ExperimentalREN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
XmAb 2513
go.drugbank.com/drugs/DB06324InvestigationalXmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types.
KD3010
go.drugbank.com/drugs/DB05188ExperimentalKD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
NV-18
go.drugbank.com/drugs/DB05886ExperimentalNV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. … Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer
GlycoPEG-GCSF
go.drugbank.com/drugs/DB06022ExperimentalGlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
AdPEDF
go.drugbank.com/drugs/DB05138ExperimentalAdPEDF is under development for the treatment of wet age-related macular degeneration (AMD).